176 related articles for article (PubMed ID: 37448364)
1. STAT3 Signaling Axis and Tamoxifen in Breast Cancer: A Promising Target for Treatment Resistance.
Zamanian MY; Golmohammadi M; Alalak A; Kamiab Z; Obaid R; Ramírez-Coronel AA; Hjazi A; Abosaooda M; Mustafa Y; Heidari M; Verma A; Nazari Y; Bazmandegan G
Anticancer Agents Med Chem; 2023; 23(16):1819-1828. PubMed ID: 37448364
[TBL] [Abstract][Full Text] [Related]
2. Essential role of Notch4/STAT3 signaling in epithelial-mesenchymal transition of tamoxifen-resistant human breast cancer.
Bui QT; Im JH; Jeong SB; Kim YM; Lim SC; Kim B; Kang KW
Cancer Lett; 2017 Apr; 390():115-125. PubMed ID: 28108315
[TBL] [Abstract][Full Text] [Related]
3. SIRT4 enhances the sensitivity of ER-positive breast cancer to tamoxifen by inhibiting the IL-6/STAT3 signal pathway.
Xing J; Li J; Fu L; Gai J; Guan J; Li Q
Cancer Med; 2019 Nov; 8(16):7086-7097. PubMed ID: 31573734
[TBL] [Abstract][Full Text] [Related]
4. KLF4 overcomes tamoxifen resistance by suppressing MAPK signaling pathway and predicts good prognosis in breast cancer.
Jia Y; Zhou J; Luo X; Chen M; Chen Y; Wang J; Xiong H; Ying X; Hu W; Zhao W; Deng W; Wang L
Cell Signal; 2018 Jan; 42():165-175. PubMed ID: 28988130
[TBL] [Abstract][Full Text] [Related]
5. STAT3-RANTES autocrine signaling is essential for tamoxifen resistance in human breast cancer cells.
Yi EH; Lee CS; Lee JK; Lee YJ; Shin MK; Cho CH; Kang KW; Lee JW; Han W; Noh DY; Kim YN; Cho IH; Ye SK
Mol Cancer Res; 2013 Jan; 11(1):31-42. PubMed ID: 23074171
[TBL] [Abstract][Full Text] [Related]
6. Tamoxifen stimulates the growth of cyclin D1-overexpressing breast cancer cells by promoting the activation of signal transducer and activator of transcription 3.
Ishii Y; Waxman S; Germain D
Cancer Res; 2008 Feb; 68(3):852-60. PubMed ID: 18245487
[TBL] [Abstract][Full Text] [Related]
7. HOXB13 mediates tamoxifen resistance and invasiveness in human breast cancer by suppressing ERα and inducing IL-6 expression.
Shah N; Jin K; Cruz LA; Park S; Sadik H; Cho S; Goswami CP; Nakshatri H; Gupta R; Chang HY; Zhang Z; Cimino-Mathews A; Cope L; Umbricht C; Sukumar S
Cancer Res; 2013 Sep; 73(17):5449-58. PubMed ID: 23832664
[TBL] [Abstract][Full Text] [Related]
8. Indoleamine 2,3-dioxygenase 1 regulates breast cancer tamoxifen resistance through interleukin-6/signal transducer and activator of transcription.
Zhao X; Jiang Y; Xu M; Hu J; Feng N; Deng H; Lu C; Huang T
Toxicol Appl Pharmacol; 2022 Apr; 440():115921. PubMed ID: 35157906
[TBL] [Abstract][Full Text] [Related]
9. [Involvement of epidermal growth factor receptor signaling pathway in tamoxifen resistance of MCF-7 cells].
Zhen LL; Zhu X; Zheng W; Wang XY; Wu ZY
Ai Zheng; 2006 Jul; 25(7):839-43. PubMed ID: 16831274
[TBL] [Abstract][Full Text] [Related]
10. Targeting autophagy with tamoxifen in breast cancer: From molecular mechanisms to targeted therapy.
Zamanian MY; Golmohammadi M; Nili-Ahmadabadi A; Alameri AA; Al-Hassan M; Alshahrani SH; Hasan MS; Ramírez-Coronel AA; Qasim QA; Heidari M; Verma A
Fundam Clin Pharmacol; 2023 Dec; 37(6):1092-1108. PubMed ID: 37402635
[TBL] [Abstract][Full Text] [Related]
11. CUL4B renders breast cancer cells tamoxifen-resistant via miR-32-5p/ER-α36 axis.
Wang Y; Pan X; Li Y; Wang R; Yang Y; Jiang B; Sun G; Shao C; Wang M; Gong Y
J Pathol; 2021 Jun; 254(2):185-198. PubMed ID: 33638154
[TBL] [Abstract][Full Text] [Related]
12. A miR-26a/E2F7 feedback loop contributes to tamoxifen resistance in ER-positive breast cancer.
Liu J; Li X; Wang M; Xiao G; Yang G; Wang H; Li Y; Sun X; Qin S; Du N; Ren H; Pang Y
Int J Oncol; 2018 Oct; 53(4):1601-1612. PubMed ID: 30066905
[TBL] [Abstract][Full Text] [Related]
13. Dicer-mediated upregulation of BCRP confers tamoxifen resistance in human breast cancer cells.
Selever J; Gu G; Lewis MT; Beyer A; Herynk MH; Covington KR; Tsimelzon A; Dontu G; Provost P; Di Pietro A; Boumendjel A; Albain K; Miele L; Weiss H; Barone I; Ando S; Fuqua SA
Clin Cancer Res; 2011 Oct; 17(20):6510-21. PubMed ID: 21878538
[TBL] [Abstract][Full Text] [Related]
14. Oncoprotein HBXIP enhances HOXB13 acetylation and co-activates HOXB13 to confer tamoxifen resistance in breast cancer.
Liu B; Wang T; Wang H; Zhang L; Xu F; Fang R; Li L; Cai X; Wu Y; Zhang W; Ye L
J Hematol Oncol; 2018 Feb; 11(1):26. PubMed ID: 29471853
[TBL] [Abstract][Full Text] [Related]
15. UBR5 over-expression contributes to poor prognosis and tamoxifen resistance of ERa+ breast cancer by stabilizing β-catenin.
Yang Y; Zhao J; Mao Y; Lin G; Li F; Jiang Z
Breast Cancer Res Treat; 2020 Dec; 184(3):699-710. PubMed ID: 32914356
[TBL] [Abstract][Full Text] [Related]
16. Differential regulation of ErbB2 expression by cAMP-dependent protein kinase in tamoxifen-resistant breast cancer cells.
Yang JW; Kim MR; Kim HG; Kim SK; Jeong HG; Kang KW
Arch Pharm Res; 2008 Mar; 31(3):350-6. PubMed ID: 18409049
[TBL] [Abstract][Full Text] [Related]
17. Ginsenoside Rg3 overcomes tamoxifen resistance through inhibiting glycolysis in breast cancer cells.
Zhao W; Ma J; Zhang Q; Zhang H; Ma W; Li S; Piao Y; Zhao S; Dai S; Tang D
Cell Biol Int; 2024 Apr; 48(4):496-509. PubMed ID: 38225685
[TBL] [Abstract][Full Text] [Related]
18. Proteomic time course of breast cancer cells highlights enhanced sensitivity to Stat3 and Src inhibitors prior to endocrine resistance development.
Madden SF; Cremona M; Farrelly AM; Low WH; McBryan J
Cancer Gene Ther; 2023 Feb; 30(2):324-334. PubMed ID: 36266450
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of STAT3 enhances sensitivity to tamoxifen in tamoxifen-resistant breast cancer cells.
Moon SY; Lee H; Kim S; Hong JH; Chun SH; Lee HY; Kang K; Kim HS; Won HS; Ko YH
BMC Cancer; 2021 Aug; 21(1):931. PubMed ID: 34407787
[TBL] [Abstract][Full Text] [Related]
20. Role of PKC-ERK signaling in tamoxifen-induced apoptosis and tamoxifen resistance in human breast cancer cells.
Li Z; Wang N; Fang J; Huang J; Tian F; Li C; Xie F
Oncol Rep; 2012 Jun; 27(6):1879-86. PubMed ID: 22427054
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]